Axovant Sciences Ltd - Company & Market Research Reports

Axovant Sciences is a biopharmaceutical company that focuses on developing and commercializing novel therapeutics for the treatment of dementia in the United States and Europe. Its best known product, intepirdine, is a selective 5-HT6 receptor antagonist. It is currently in Phase III clinical trial for the treatment of Alzheimer's disease and in Phase II clinical trial for treating dementia. The company was formerly known as Roivant Neurosciences. Founded in 2014, it is based in Hamilton, Bermuda.

From
From
Alzheimer's Disease - Pipeline Review, H2 2018 - Product Thumbnail Image

Alzheimer's Disease - Pipeline Review, H2 2018

  • Drug Pipelines
  • 1333 Pages
From
Alzheimer's Disease - Pipeline Review, H1 2018 - Product Thumbnail Image

Alzheimer's Disease - Pipeline Review, H1 2018

  • Drug Pipelines
  • 1203 Pages
From
From
Dementia - Pipeline Review, H2 2018 - Product Thumbnail Image

Dementia - Pipeline Review, H2 2018

  • Drug Pipelines
  • 302 Pages
From
Dementia - Pipeline Review, H1 2018 - Product Thumbnail Image

Dementia - Pipeline Review, H1 2018

  • Drug Pipelines
  • 260 Pages
From
Parkinson's Disease - Pipeline Review, H1 2018 - Product Thumbnail Image

Parkinson's Disease - Pipeline Review, H1 2018

  • Drug Pipelines
  • 881 Pages
From
From
From
From
Loading Indicator
adroll